Chase Therapeutics Corporation
Chase Therapeutics is an early-stage, product-based specialty pharmaceutical company focused on developing better treatments for brain disease. It aims to rapidly translate advances in neurosciences into safer and more effective treatments for neurologic and psychiatric diseases, with a pipeline including promising drugs in mid-stage development for conditions like Parkinson’s disease and major depressive disorder. The company's mission is to improve the quality of life for patients with brain diseases and their caregivers through transformative therapeutic innovation.
Industries
Nr. of Employees
medium (51-250)
Chase Therapeutics Corporation
1825 K Street NW, Suite 510 Washington, DC 20006
Patents
Products
Clinical-stage small-molecule therapeutic candidate for Parkinson's disease (symptomatic and neuroprotective)
A small-molecule therapeutic program developed for symptomatic relief and potential neuroprotective benefit in Parkinson's disease and related movement/cognitive disorders; program reported as entering Phase 2 clinical evaluation.
Clinical-stage small-molecule therapeutic candidate for major depressive disorder
A small-molecule program for symptomatic treatment of major depressive disorder reported as entering Phase 2 clinical evaluation, aimed at faster onset and improved tolerability.
Non-invasive diagnostic bioassay for Parkinson's disease (in development)
A bioassay under development intended to diagnose and stage Parkinson's disease and to function as an early response outcome measure in clinical trials of neuroprotective interventions.
Clinical-stage small-molecule therapeutic candidate for Parkinson's disease (symptomatic and neuroprotective)
A small-molecule therapeutic program developed for symptomatic relief and potential neuroprotective benefit in Parkinson's disease and related movement/cognitive disorders; program reported as entering Phase 2 clinical evaluation.
Clinical-stage small-molecule therapeutic candidate for major depressive disorder
A small-molecule program for symptomatic treatment of major depressive disorder reported as entering Phase 2 clinical evaluation, aimed at faster onset and improved tolerability.
Non-invasive diagnostic bioassay for Parkinson's disease (in development)
A bioassay under development intended to diagnose and stage Parkinson's disease and to function as an early response outcome measure in clinical trials of neuroprotective interventions.
Services
Sourcing research support and capabilities through collaborations with academic investigators, research institutions, and industry partners to advance discovery and development programs.
Management and coordination of clinical development activities for CNS drug candidates, including support for Phase 1 and Phase 2 studies.
Development of non-invasive bioassays intended for diagnosis, staging, and early response assessment in Parkinson's disease and related disorders.
Sourcing research support and capabilities through collaborations with academic investigators, research institutions, and industry partners to advance discovery and development programs.
Management and coordination of clinical development activities for CNS drug candidates, including support for Phase 1 and Phase 2 studies.
Development of non-invasive bioassays intended for diagnosis, staging, and early response assessment in Parkinson's disease and related disorders.
Expertise Areas
- Clinical trial management for CNS indications
- Translational neuroscience and neurotherapeutics
- Biomarker and diagnostic assay development
- Drug discovery and preclinical development for CNS disorders
Key Technologies
- Small-molecule therapeutic development
- Biomarker-based diagnostic assays
- Preclinical neuropharmacology models
- Clinical protocol design and outcome measures